RESEARCH ARTICLE

Pain during pars plana vitrectomy following sub-Tenon versus peribulbar anesthesia: A randomized trial

Jefferson A. S. Ribeiro,1,2* Daniel S. Ribeiro2*, Ingrid U. Scott3,4*, João Abrão5*, Rodrigo Jorge2*

1 Superior School of Health Sciences, Amazonas State University, Manaus, AM, Brazil, 2 Department of Ophthalmology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil, 3 Department of Ophthalmology, Penn State College of Medicine, Hershey, Pennsylvania, United States of America, 4 Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania, United States of America, 5 Department of Biomechanics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil

* These authors contributed equally to this work.

OPEN ACCESS

Citation: Ribeiro JAS, Ribeiro DS, Scott IU, Abrão J, Jorge R (2020) Pain during pars plana vitrectomy following sub-Tenon versus peribulbar anesthesia: A randomized trial. PLoS ONE 15(8): e0236624. https://doi.org/10.1371/journal.pone.0236624

Editor: Luciano Quaranta, University of Pavia, ITALY

Received: January 28, 2020
Accepted: July 3, 2020
Published: August 6, 2020

Copyright: © 2020 Ribeiro et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: The author(s) received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

Abstract

Purpose
To compare pain during pars plana vitrectomy (PPV) following topical lidocaine jelly and sub-Tenon anesthesia versus peribulbar anesthesia.

Methods
Prospective, single-center, randomized study. Patients scheduled for PPV for macular hole (MH) or epiretinal membrane (ERM) at the Retina and Vitreous Section of the Department of Ophthalmology, Ribeirão Preto Medical School, University of São Paulo were randomly assigned to one of two groups in a 1:1 allocation ratio. Patients assigned to Group ST received topical anesthesia with 2% lidocaine jelly followed by sub-Tenon anesthesia with 2–4 ml of 1% ropivacaine. Patients assigned to PB received peribulbar anesthesia with 4–6 ml of 1% ropivacaine. After PPV, patients in both groups were asked to rate the level of pain they felt during the entire procedure (including anesthesia administration and PPV) by pointing at a 0–100 Visual Analogue Pain Scale (VAS). Data regarding demographics, patient characteristics and surgical features were also collected.

Results
Fifty-four patients were enrolled in the study (26 in Group ST and 28 in Group PB). Baseline characteristics, including age, gender, and presence of comorbidities, were similar in both groups. The surgery performed was PPV alone in 10 and 14 patients in the ST and PB groups, respectively, and combined phacoemulsification and PPV in 16 and 14 patients in the ST and PB groups, respectively (p = 0.39, Pearson). Surgery duration (mean ± SD minutes) was similar in the two groups (62 ± 12 for ST and 70 ± 20 for PB, p = 0.09, t-Test). No patients needed supplemental topical or intravenous anesthesia during surgery. No sight-
life-threatening complication was observed in either group. VAS score was significantly lower in the ST compared to the PB group (median (interquartile range) was 1 (2.25–0) in the ST group compared to 11.5 (29.75–5) in the PB group, \( p < 0.0001 \), Wilcoxon).

**Conclusion**

In this study of patients who underwent PPV for MH or ERM, topical followed by sub-Tenon anesthesia was more effective in controlling pain during the whole vitrectomy procedure than peribulbar anesthesia. Compared to peribulbar anesthesia which is administered with a sharp needle, sub-Tenon anesthesia administered with a blunt cannula may be associated with a reduced risk of such adverse events as globe perforation, retrobulbar hemorrhage, and inadvertent injection of anesthesia into the optic nerve sheath.

---

**Introduction**

Ocular anesthesia began with the demonstration of the anesthetic effect of topical cocaine for eye surgery in 1884 by Koller [1]. Later in that year, Knapp described a simple and effective method for retrobulbar anesthesia, which had limited use at that time due to the toxicity of cocaine administered by this way [1]. During the early part of the 20th century, cataract surgery was performed under topical cocaine anesthesia in order to reduce the risk of complications related to orbital or general anesthesia [2]. The development of regional anesthesia, as well as other anesthetic agents such as procaine in 1905 [2], made regional block more common in ophthalmology, first by retrobulbar block and then by peribulbar block. In the 1990s, the development of ophthalmic procedures, such as modern phacoemulsification techniques, allowing safe and rapid cataract extraction [2], and topical anesthesia made this option a favorite of many surgeons [3], although intracanal or peribulbar blocks may be preferred for other anterior segment surgeries, such as trabeculectomy or penetrating keratoplasty [2].

Anesthesia for vitreoretinal surgery is challenging since such surgery is typically longer than cataract phacoemulsification surgery, and patients frequently have such comorbidities as diabetes and hypertension [4, 5]. Traditionally, general anesthesia was most commonly used for vitreoretinal surgery, but more recently there has been a trend for local anesthesia, primarily peribulbar/retrobulbar [6–9]. However, the use of sharp needles to perform local anesthesia is associated with such complications as retrobulbar hemorrhage and injection of anesthesia into the optic nerve sheath which may result in death [10–12].

Three main drugs, all amino amides, are used for regional eye blocks: lidocaine, bupivacaine and ropivacaine. Lidocaine is the fastest-acting of these drugs due to its penetration into tissue, but it also has the shortest duration of action. Bupivacaine is about four times more potent than lidocaine and is similar to ropivacaine [4, 13], although some recent studies suggest that ropivacaine is a better choice of local anesthetic solution for patients undergoing primary vitreoretinal surgery compared with 0.5% bupivacaine [14–16] due to ropivacaine’s lesser cardiovascular effects compared with bupivacaine [17]. Although lidocaine, ropivacaine and bupivacaine are all effective for regional ophthalmic anesthesia, ropivacaine is the drug of choice for ocular blocks due to its duration of action and safety profile [13].

With the adoption of small-gauge pars plana vitrectomy (PPV) and the expansion of surgical indications, less invasive anesthetic methods such as topical eye drops [18–20] and sub-Tenon injection [21–24] have increasingly been used. Optimal anesthesia would not only...
protect against pain, but would also reduce risks, avoid the oculocardiac reflex, and permit early patient mobilization [5].

Sub-Tenon anesthesia has been reported to provide effective anesthesia for vitreoretinal surgery while reducing the risks of using a sharp needle [21–24]. The primary objective of the current study was to compare pain, measured by a visual analogue scale (VAS), during PPV following topical lidocaine jelly and sub-Tenon anesthesia versus peribulbar anesthesia only. In addition, safety outcomes were assessed.

Methods
The study protocol (available as Supplementary material, S1 Study protocol) adhered to the tenets of the Declaration of Helsinki and was approved by the local Institutional Review Board, Comitê de Ética em Pesquisa do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, on December 18th, 2018, and registered in the ClinicalTrials.gov under the number NCT03902925. All participants gave written informed consent before entering into the study. The authors confirm that all ongoing and related trials for this intervention are registered. Our trial was registered at ClinicalTrials.gov after patient recruitment began because we prioritized registration of our study at a national regulation agency website for clinical studies (http://plataformabrasil.saude.gov.br). Enrollment started on January 1st, 2019, and finished on August 31st, 2019, and patients were followed until October 31st, 2019.

In this prospective, single-center, randomized study, patients who needed PPV for macular hole (MH) or epiretinal membrane (ERM) at the Retina and Vitreous Section of the Department of Ophthalmology, Ribeirão Preto Medical School, University of São Paulo were invited to participate. Patients were excluded if they were less than 18 years-old or had a history of PPV or scleral buckle surgery in the study eye, any previous ocular surgery in the study eye in the last 3 months, uncontrolled hypertension or any other medical or psychological condition that precluded the patient from performing the study procedures or providing informed consent. After providing verbal and written informed consent, patients were assigned to one of two groups in an allocation ratio of 1:1 by simple randomisation. A technician was asked to pick up one of two identical opaque envelopes, one containing the designation for Sub-Tenon group and the other containing the designation for Peribulbar. The next included patient was automatically assigned to the treatment group specified in the second envelope. Patients were masked to the type of anesthesia used. Although all patients were under intravenous sedation, the masking effect for patients may have been compromised since the two anesthetic techniques induce different sensations: ST uses topical jelly and conjunctival dissection, while PB uses eye drops and transcutaneous injection. In Group ST, patients received topical anesthesia with 2% lidocaine jelly followed by sub-Tenon anesthesia with 2–4 ml of 1% ropivacaine. In Group PB, patients received peribulbar anesthesia only with 4–6 ml of 1% ropivacaine. After PPV, patients in both groups were asked to rate the level of pain they felt during the entire procedure (including anesthesia administration and PPV) by pointing at a 0–100 VAS. A masked operator applied the VAS to patients. The operator did not participate in the surgical procedure or anesthesia, and all patients received a white tissue shield to cover the operated eye, so the operator was unable to infer what type of anesthesia was performed. Data regarding demographics, patient characteristics and surgical aspects were also collected.

Sample size was calculated based on other studies [22, 25], considering a difference greater than 20 units in the mean pain score between groups to be significant, a standard deviation of 25 units, power of 90% and type I error of 5%. The estimated sample size was 60 patients (30 in each group).
Due to the difficulty in enrolling patients, we changed the original protocol inclusion criteria for patients who needed vitrectomy for complications of diabetic retinopathy, such as retinal detachment and vitreous hemorrhage, and chose not to include these patients, including only those who needed PPV for macular hole (MH) or epiretinal membrane (ERM).

**Study procedures**

During the preoperative evaluation, each patient received a detailed ophthalmologic examination including best-corrected visual acuity (BCVA) measurement according to the Early Treatment of Diabetic Retinopathy Study (ETDRS) standard refraction protocol, applanation tonometry, biomicroscopy of the anterior segment, indirect binocular ophthalmoscopy, red-free and color fundus pictures, and optical coherence tomography. The patients were then assigned randomly to one of the two groups:

**Group ST.** in the operating room, intravenous midazolam 5 ml (5 mg/ml) was administered by the anesthesiologist. Before draping, 2% lidocaine gel was applied to the superior and inferior conjunctival fornices of the study eye, and balloon compression was then applied for 5 minutes. Patients were subsequently prepared in an aseptic manner with sterile drape and blepharostat placement for sub-Tenon anesthetic injection, which was performed through a small incision in the conjunctiva and Tenon capsule 7–10 mm posterior to the corneal limbus in the inferotemporal quadrant. Anesthetic infiltration was performed using a metallic, curved, blunt cannula, 23g x 7/8” (0.64 x 22mm) (Sterimedix, Redditch, UK). Two to four ml of 1% ropivacaine were injected until fluid reflux was observed close to the limbus.

**Group PB.** in the operating room, intravenous midazolam 5 ml (5 mg/ml) was administered by the anesthesiologist. Before draping, 3–5 proximethacaine 5 mg/ml eye drops (Aestalcon®) were placed on the conjunctiva and cornea of the study eye. After that but before draping, a peribulbar injection was performed under aseptic conditions in the operating room. Peribulbar injection was performed with a 30 x 0.7 mm 22G sharp needle in the temporal aspect of the inferior eyelid, using as a reference the transition from the middle to the outer third of the orbital rim. The needle was infiltrated parallel to the ocular globe toward the greater sphenoid wing. Four to six ml of 1% ropivacaine were injected until a drop of the upper eyelid was visualized. Balloon compression was then applied for 5 minutes. Patients were subsequently prepared in an aseptic manner with sterile drape and blepharostat placement for vitrectomy.

Ropivacaine was the drug used for the infiltrative anesthesia in both groups. Ropivacaine is an aminoamide, local, long-acting anesthetic from the group of the piperidines, which includes bupivacaine [26]. Ropivacaine inhibits sodium ion influx, thus blocking impulse conduction in nerve fibers [27]. It produces a rapid block of both A and C fibers involved in pain transmission [26, 27]. Compared to bupivacaine, ropivacaine is less lipophilic and is less likely to penetrate large myelinated motor fibers [27]. Therefore, it has the advantage of producing a motor block that is slower in onset, less intense and shorter in duration than that induced by bupivacaine at similar doses for epidural anesthesia [26]. However, ropivacaine for peribulbar anesthesia has a similar profile to bupivacaine regarding the latency and duration of motor block [28]. Further, ropivacaine has a favourable cardiotoxic profile compared to bupivacaine [26, 27].

The surgical procedure performed in both groups was a 23-gauge PPV which was combined with phacoemulsification and intraocular lens placement if significant lens opacity was present. PPV was performed by one of two experienced retina surgeons and consisted of: 1) inferotemporal placement of a 23-gauge valved trocar and infusion line for balanced salt solution (Alcon, Texas, Fortworth) infusion; 2) superonasal and superotemporal placement of
23-gauge valved trocars; 3) PPV; 4) the posterior hyaloid was stained with triamcinolone acetone and detachment of the posterior hyaloid was attempted in all patients without a pre-existing posterior vitreous detachment. In patients with a MH, brilliant blue dye was used to stain the internal limiting membrane, which was then peeled for 360-degrees around the hole; 5) endolaser photocoagulation was performed if needed for retinal breaks; 6) fluid-gas exchange and vitreous substitute placement was performed if indicated; and 7) removal of the 23-gauge trocars and injection of subconjunctival 4mg of dexamethasone. A metal shield was placed over the operative eye, so that the pain examiner could not determine the type of anesthesia used in each case.

**Evaluation of pain**

Forty to sixty minutes after the end of the surgery, a masked examiner used a 100-point VAS for pain score estimation [29–35]. The numbers of the scale were visible only on the examiner’s side, so that patients could not choose the same number to guide pain ratings. Prior to rating level of pain, each patient was asked to slide the marker along the entire scale, with the aid of the examiner. At point 0, the examiner clarified to the patient that this point of the scale represented “no pain at all”; at point 100, the examiner clarified to the patient that this point of the scale represented “the most intense pain one could ever feel”. The patient was asked about the intensity of pain during the whole procedure (anesthesia plus vitrectomy).

**Statistical analysis**

For data analysis, we included only patients who completed the study and underwent the proposed intervention in the designated treatment group. Group comparison of VAS score was performed with the Wilcoxon Rank-test. The Pearson test was used for nominal variables and a two-tailed t-Test was applied to the other comparisons between groups. All tests considered a significance level of $p < 0.05$. Software JMP 8.0.2 SAS Institute 2009 was used for statistical analysis.

**Results**

Fifty-four patients were included in the study (26 in the ST group and 28 in the PB group) between January 2019 and August 2019. One patient in the PB group was excluded due to the administration of morphine preoperatively and one patient in the ST group was excluded due to the need for combined glaucoma surgery (Fig 1). Baseline patient characteristics and surgical features of each group are summarized in Table 1. There were no significant differences between the groups with respect to gender, age, presence of comorbidities (diabetes and arterial hypertension), surgical indication (MH or ERM), proportion of participants who underwent PPV versus combined phacoemulsification with intraocular lens implantation and PPV, proportion of participants who received endolaser, and duration of surgery. Ten of the 26 patients in the ST group and 14 of the 28 patients in the PB group had previously undergone cataract surgery.

No patient needed supplemental local or intravenous anesthesia intraoperatively, and no patient needed medication for controlling pain postoperatively. No sight- or life-threatening complication was observed in either group. In the ST group, the surgeon noted some patients lacked intraoperative akinesia and demonstrated some rapid eye movements during surgery, although this was not defined as main surgical complication and as such it was not accounted for.
CONSORT 2010 Flow Diagram

Enrollment

Assessed for eligibility (n=58)

Excluded (n=2)
  - Not meeting inclusion criteria (n=2)

Randomized (n=56)

Allocated to intervention ST (n=27)
  - Received allocated intervention (n=26)
  - Did not receive allocated intervention (due to the need of combined glaucoma surgery) (n=1)

Allocated to intervention (n=29)
  - Received allocated intervention (n=28)
  - Did not receive allocated intervention (due to the administration of morphine preoperatively) (n=1)

Follow-Up

Lost to follow-up (give reasons) (n=0)
Discontinued intervention (give reasons) (n=0)

Lost to follow-up (give reasons) (n=0)
Discontinued intervention (give reasons) (n=0)

Analysis

Analysed (n=26)
  - Excluded from analysis (give reasons) (n=0)

Analysed (n=28)
  - Excluded from analysis (give reasons) (n=0)

Fig 1. CONSORT flowchart.

https://doi.org/10.1371/journal.pone.0236624.g001
Main outcome measure

Fig 2 shows the distribution of pain level ratings in both groups. The median (interquartile range) whole procedure pain was 1 (2.25–0) in the ST group compared to 11.5 (29.75–5) in the PB group ($p < 0.0001$; Wilcoxon). Thirteen of the 26 patients from the ST group rated their pain level a zero, meaning they experienced no pain at all, and the maximum pain score was 11 (in 3 participants) with a median score of 1. In the PB group, only 2 of the 28 patients rated...
their pain level a zero, seven participants rated their pain level higher than 30, and the median pain level rating was 11.5.

**Discussion**

To our knowledge, and based on a computerized search of the PubMed database, this is the first prospective study to compare pain during PPV following topical lidocaine jelly and sub-Tenon anesthesia versus peribulbar anesthesia only. Sub-Tenon anesthesia was more effective than peribulbar anesthesia for controlling pain during PPV. This may be due to superior effectiveness of the sub-Tenon mode of administration in delivering the anesthetic agent posteriorly to the globe, or perhaps a sub-Tenon injection preceded by topical anesthesia is less painful than a peribulbar injection. Peribulbar anesthesia is not precisely placed near its site of action, so its efficacy depends on the anesthetic solution spreading through the peribulbar tissue; if a sufficient amount of the anesthetic does not reach the retrobulbar space, adequate analgesia will not be achieved. Results of the current study are different from those reported in the literature regarding comparison of sub-Tenon versus retrobulbar anesthesia for vitrectomy surgery [22, 36], in which both techniques were equally effective.

In the current study, no patient needed supplemental local or intravenous anesthesia intraoperatively, and no patient needed medication for controlling pain postoperatively. In contrast, in the study of Lai et al. published in 2000 [22], supplemental anesthesia was required in 37% of patients who received sub-Tenon anesthesia, and 70% of patients required additional intravenous sedation for controlling pain. Of note, a longer duration of surgery was recorded for both groups in the latter study compared to ours (mean ± SD, 96.6 ± 42.6 and 104.2 ± 54.8, for retrobulbar and sub-Tenon’s capsule groups respectively) [22]. The difference between the results of the latter study and ours may be due to the shorter duration of surgery and lack of scleral buckling and cryotherapy in our series.

Traditionally, peribulbar and retrobulbar blocks are administered with sharp needles; however, the latter requires a longer needle, such as an Atkinson retrobulbar needle, to penetrate the intraconal space [37]. There are blunt cannulas, (usually curved, designed to improve the comfort and safety of patients who need vitrectomy [38], through which the anesthetic solution can be administered in the sub-Tenon space, with some variations of technique, as described by Young-Zvasara et al., 2019 [39], using a lacrimal cannula through the sub-Tenon space for a retrobulbar approach. In our study, we used a sharp needle for peribulbar injection, because that is the routine of our service, and it is what many practices use, due to its effectiveness, ease of acquisition and low cost.

Anesthesia-related adverse events were not observed in our study. The primary advantage of sub-Tenon over peribulbar and retrobulbar anesthesia is a more favorable safety profile [21–23, 36, 40, 41], since the use of a blunt cannula with sub-Tenon injections compared to a sharp needle with peribulbar and retrobulbar injections reduces the risks of such adverse events as globe perforation and retrobulbar hemorrhage. However, rare adverse events, including scleral perforation and retinal ischemia, associated with sub-Tenon injection have been described, particularly in patients with previous ocular surgery, conjunctival scarring and thinned sclera [42–45], Frieman & Friedberg, 2001 [42], reported a patient with a compromised sclera for whom administration of sub-Tenon anesthesia required a cutting action with scissors. In this situation, it is recommended to use blunt scissors and to consider another type of anesthesia when the cannula does not have an easy passage into the sub-Tenon’s space [40]; access from another quadrant of the eye can also be attempted. Eyes with myopic staphyloma are at increased risk of globe perforation during peribulbar and retrobulbar injection [10] and,
although sub-Tenon anesthesia may be safer, care must be taken with these eyes during a sub-
Tenon approach. There are no reports of complications related to eyes with short axial length,
and sub-Tenon anesthesia can be safely performed in these eyes [46].

One potential limitation of our study was the administration of intravenous midazolam
prior to sub-Tenon or peribulbar injection; however, this single dose of midazolam was pro-
vided to patients in both study groups and, therefore, cannot explain the difference in pain
level ratings between the groups. Another point to consider is that preoperative anxiety has
been reported to be associated with intraoperative pain perception [47, 48], and the sub-
Tenon approach may be associated with less anxiety than the retrobulbar approach since
patients receiving sub-Tenon anesthesia do not see a needle moving toward them as is the case
with peribulbar injections [21].

Another limitation of the current study is the fact that it included only patients undergoing
PPV for MH or ERM; thus, the results of this study may not be applicable to patients undergo-
ning PPV for other indications that require such intraoperative procedures as scleral buckling,
cryotherapy or photocoagulation which are known to be associated with discomfort. Sub-
Tenon’s anesthesia has been used in other eye surgeries, mainly for cataract surgery, but also
for trabeculotomy, strabismus surgery and optic nerve sheath fenestration [49–51] and, in the
case of vitreoretinal procedures, sub-Tenon’s anesthesia has been used for scleral buckle sur-
gery and vitrectomy for conditions other than macular diseases [22, 52]. Due to its theoreti-
cally safer profile, it may be the preferred method of anesthesia administration for cases that
do not require general anesthesia and when more analgesia and akinesia are needed compared
to what can be achieved with topical anesthesia (eye drops and jelly).

Finally, the absence of akinesia associated with the sub-Tenon approach is a limitation of
this technique. However, some authors have reported good akinesia for vitreous surgery with
sub-Tenon anesthesia [24, 41, 53], and there are some studies that have used topical anesthesia
for vitrectomy and have not reported complications due to eye movements [19, 20, 54]. We
believe that good eye stabilization can be achieved when both upper trocars are fitted with
instruments, preventing retinal injury from inadvertent eye movements.

**Conclusion**

In this study of patients who underwent PPV for MH or ERM, topical followed by sub-Tenon
anesthesia was more effective in controlling pain during the whole vitrectomy procedure than
peribulbar anesthesia. Compared to peribulbar anesthesia which is administered with a sharp
needle, sub-Tenon anesthesia administered with a blunt cannula may be associated with a
reduced risk of such adverse events as globe perforation, retrobulbar hemorrhage, and inad-
vertent injection of anesthesia into the optic nerve sheath, however our study was not powered
to detect this events. Further studies are necessary to confirm our preliminary findings.

**Supporting information**

S1 Checklist. CONSORT 2010 checklist.
(DOC)

S1 Study protocol. Study protocol.
(DOCX)

S1 Dataset. Raw data.
(PDF)
Author Contributions

Conceptualization: Jefferson A. S. Ribeiro, Daniel S. Ribeiro, Ingrid U. Scott, João Abrão, Rodrigo Jorge.

Data curation: Jefferson A. S. Ribeiro, Daniel S. Ribeiro, Rodrigo Jorge.

Formal analysis: Jefferson A. S. Ribeiro, Ingrid U. Scott, Rodrigo Jorge.

Investigation: Jefferson A. S. Ribeiro, Daniel S. Ribeiro, Ingrid U. Scott, João Abrão, Rodrigo Jorge.

Methodology: João Abrão, Rodrigo Jorge.

Project administration: Daniel S. Ribeiro, Rodrigo Jorge.

Supervision: João Abrão, Rodrigo Jorge.

Writing – original draft: Jefferson A. S. Ribeiro, Daniel S. Ribeiro, Ingrid U. Scott, João Abrão, Rodrigo Jorge.

Writing – review & editing: Jefferson A. S. Ribeiro, Ingrid U. Scott, Rodrigo Jorge.

References

1. Atkinson WS. The development of ophthalmic anesthesia. Am J Ophthalmol. 1961; 51:1–14. https://doi.org/10.1016/0002-9394(61)91304-6 PMID: 13684987

2. Freeman JM, Freeman JFD. Retrobulbar and posterior peribulbar anesthesia for ophthalmic surgery. Ophthalmol Clin North Am. 1998; 11:39–45.

3. Moster MR, Azuara-Blanco A. Ocular anesthesia in the new millennium. Ophthalmol Clin North Am. 2000; 13:131–139.

4. Stead SW, Miller KM. Anesthesia for ophthalmic surgery. In: Spaeth GL, editor. Ophthalmic Surgery: principles and practice. 3rd edition. Philadelphia: Saunders; 2003. pp. 15–25.

5. Murat J, Chauvaud D. [Evaluation of a simplified protocol of local regional anesthesia for the surgery of the posterior segment]. J Fr Ophtalmol. 1993; 16:254–258. PMID: 8326106

6. Charles S, Fanning GL. Anesthesia considerations for vitreoretinal surgery. Ophthalmol Clin North Am. 2006; 19:239–243. https://doi.org/10.1016/j.ohc.2006.02.002 PMID: 16701161

7. Costen MT, Newsom RS, Wainwright AC, Luff AJ, Canning CR. Expanding role of local anaesthesia in vitreoretinal surgery. Eye (Lond). 2005; 19:755–761.

8. Knight HM, Newsom RB, Canning CR, Luff AJ, Wainwright AC. Local anaesthesia for vitreoretinal surgery: an audit of patient and surgical experience. Eur J Ophthalmol. 2001; 11:366–371. https://doi.org/10.1177/1120672101101100409 PMID: 11820309

9. Newsom RS, Wainwright AC, Canning CR. Local anaesthesia for 1221 vitreoretinal procedures. Br J Ophthalmol. 2001; 85:225–227. https://doi.org/10.1136/bjo.85.2.225 PMID: 1159492

10. Tognetto D, di Lauro MT, Fanni D, Zagidullina A, Michelone L, Ravalico G. Iatrogenic retinal traumas in ophthalmic surgery. Graefes Arch Clin Exp Ophthalmol. 2008; 246:1361–1372. https://doi.org/10.1007/s00417-008-0879-3 PMID: 18604549

11. Gillow JT, Aggarwal RK, Kirkby GR. Ocular perforation during peribulbar anaesthesia. Eye (Lond). 1996; 10:533–536.

12. Edge R, Navon S. Scleral perforation during retrobulbar and peribulbar anaesthesia: risk factors and outcome in 50,000 consecutive injections. J Cataract Refract Surg. 1999; 25:1237–1244. https://doi.org/10.1016/s0886-3350(99)00143-1 PMID: 10476508

13. Zhou YL, Tong Y, Wang YX, Zhao PO, Wang ZY. A prospective, randomised, double-masked comparison of local anaesthetic agents for vitrectomy. Br J Ophthalmol. 2017; 101:1016–1021. https://doi.org/10.1136/bjophthalmol-2016-309780 PMID: 28174153

14. Jaichandran VV, Ramam R, Gella L, Sharma T. Local anesthetic agents for vitreoretinal surgery: no advantage to mixing solutions. Ophthalmology. 2015; 122:1030–1033. https://doi.org/10.1016/j.ophtha.2014.11.026 PMID: 25582785
15. Jaichandran VV, Srinivasan S, Raman S, Jagadeesh V, Raman R. A prospective comparison of the efficacy of 0.5% bupivacaine vs 0.75% ropivacaine in peribulbar anesthesia for vitreoretinal surgery. Indian J Ophthalmol. 2020; 68:153–156. https://doi.org/10.4103/ijo.IJO_239_19 PMID: 31856495

16. Gioia L, Prandi E, Codenotti M, Casati A, Fanelli G, Torri TM, et al. Peribulbar anesthesia with either 0.75% ropivacaine or a 2% lidocaine and 0.5% bupivacaine mixture for vitreoretinal surgery: a double-blind study. Anesth Analg. 1999; 89:739–742. https://doi.org/10.1097/00000539-199909000-00039 PMID: 10475316

17. Kalilho H, Puska P, Summanen P, Paloeimo M, Mauuksela EL. Retrobulbar/peribulbar block with 0.2% ropivacaine or 1% lidocaine for transscleral cyclophotoagulation or retinal panphotocoagulation. Reg Anesth Pain Med. 1999; 24:341–346. https://doi.org/10.1016/s1098-7339(99)90109-8 PMID: 10445774

18. Tang S, Lai P, Lai M, Zou Y, Li J, Li S. Topical anesthesia in transconjunctival sutureless 25-gauge vitrectomy for macular-based disorders. Ophthalmologica. 2007; 221:65–68. https://doi.org/10.1159/000096526 PMID: 17183205

19. Celiker H, Karabas L, Sahin O. A comparison of topical or retrobulbar anesthesia for 23-gauge posterior vitrectomy. J Ophthalmol. 2014; 2014:237028. https://doi.org/10.1155/2014/237028 PMID: 25485143

20. Bahcecioglu H, Unal M, Artunay O, Sarcic A, Posterior vitrectomy under topical anesthesia. Can J Ophthalmol. 2007; 42:272–277. https://doi.org/10.3129/canj ophthalmol.i07-004 PMID: 17392852

21. Li HK, Abouleish A, Grady J, Groeschel W, Gill KS. Sub-Tenon’s injection for local anesthesia in posterior segment surgery. Ophthalmology. 2000; 107:41–46. https://doi.org/10.1016/s0161-6420(99)00009-3 PMID: 10647717

22. Lai MM, Lai JC, Lee WH, Huang JJ, Patel S, Ying HS, et al. Comparison of retrobulbar and sub-Tenon’s capsule injection of local anesthetic in vitreoretinal surgery. Arch Ophthalmol. 2000; 118:1037–1043. https://doi.org/10.1001/archophthalm.118.8.1037 PMID: 10922195

23. Mein CE, Woodcock MG. Local anesthesia for vitreoretinal surgery. Retina. 1990; 10:47–49. PMID: 2343191

24. Bergman L, Berglin L, Algvere PV, Laurell CG, Stenksula S. Limbal sub-Tenon’s administration of retrobulbar anesthesia using a blunt irrigating cannula. Ophthalmic Surg Lasers. 1996; 27:106–112. PMID: 8640432

25. Bergman L, Bäckmark I, Onies H, von Euler C, Olivstedt G, Kvanta A, et al. Preoperative sub-Tenon’s capsule injection of ropivacaine in conjunction with general anesthesia in retinal detachment surgery. Ophthalmology. 2007; 114:2055–2060. https://doi.org/10.1016/j.ophtha.2006.12.031 PMID: 17445898

26. McClure JH. Ropivacaine. Br J Anaesth. 1996; 76:300–307. https://doi.org/10.1093/bja/76.2.300 PMID: 8695739

27. Kuthiala G, Chaudhary G. Ropivacaine: A review of its pharmacology and clinical use. Indian J Anaesth. 2011; 55:104–110. https://doi.org/10.4103/0019-5049.78975 PMID: 21712863

28. Magalhães E, Gouvêia CS, Oliveira KB. [Racemic bupivacaine, levobupivacaine and ropivacaine in regional anesthesia for ophthalmology—a comparative study]. Rev Assoc Med Bras. 2004; 50:195–198. https://doi.org/10.1590/s0104-42302004000200038 PMID: 15286870

29. Cintra LP, Lucena LR, Da Silva JA, Costa RA, Scott IU, Jorge R. Comparative study of analgesic effectiveness using three different anesthetic techniques for intravitreal injection of bevacizumab. Ophthalmic Surg Lasers Imaging. 2009; 40:13–18. https://doi.org/10.3928/15428877-20090101-05 PMID: 19205490

30. Bardocci A, Lofoco G, Perdicaro S, Ciucci F, Manna L. Lidocaine 2% gel versus lidocaine 4% unreserved drops for topical anesthesia in cataract surgery: a randomized controlled trial. Ophthalmology. 2003; 110:144–149. https://doi.org/10.1016/s0161-6420(02)01562-2 PMID: 12511360

31. Boezaart A, Berry R, Nell M. Topical anesthesia versus retrobulbar block for cataract surgery: the patients’ perspective. J Clin Anesth. 2000; 12:58–60. https://doi.org/10.1016/s0952-8180(00)00117-3 PMID: 10773510

32. Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimetres?. Pain. 1997; 72:95–97. https://doi.org/10.1016/s0304-3959(97)00005-5 PMID: 9272792

33. Sousa FAEF, Silva JA. [Pain assessment and measurement in clinical and research settings]. Rev Dor. 2004; 5:408–429.

34. Lucena CR, Ramos Filho JA, Messias AM, Silva JA, Almeida FP, Scott IU, et al. Panretinal photocoagulation versus intravitreal injection retreatment pain in high-risk proliferative diabetic retinopathy. Arq Bras Oftalmol. 2013; 76:18–20. https://doi.org/10.1590/s0004-27492013000100006 PMID: 23812521
35. De Faria Rodrigues A, Messias AM, Da Silva JA, Ribeiro JA, Jorge R, Scott IU. Diclofenac for panretinal photocoagulation pain. Ophthalmology. 2010; 117:2441.e1–3. https://doi.org/10.1016/j.ophtha.2010.06.008 PMID: 21129572

36. Reichstein DA, Warren CC, Han DP, Wirostko WJ. Local Anesthesia With Blunt Sub-Tenon’s Cannula Versus Sharp Retrobulbar Needle for Vitreoretinal Surgery: A Retrospective, Comparative Study. Ophthalmic Surg Lasers Imaging Retina. 2016; 47:55–59. https://doi.org/10.3928/23258160-20151214-08 PMID: 26731210

37. Bryant JS, Busbee BG, Reichel E. Overview of ocular anesthesia: past and present. Curr Opin Ophthalmol. 2011; 22:180–184. https://doi.org/10.1097/ICO.0b013e328345974c PMID: 21427572

38. Wald KJ, Weiter JJ. Modified technique of blunt cannula retrobulbar anesthesia for vitreoretinal surgery. Ophthalmic Surg. 1993; 24:336–338. PMID: 8515951

39. Young-Zvazara T, Windt J, Wijetilleka S, Wheeler L, Mcpherson R. Efficacy and Safety of a Novel Blunt Cannula Trans-Sub-Tenon’s Retrobulbar Block for Vitreoretinal Surgery. Middle East Afr J Ophthalmol. 2019; 26:163–167. https://doi.org/10.4103/meajo.MEAJO_151_18 PMID: 31619905

40. Davison M, Pradoni S, Bunce C, Rüschon H. Sub-Tenon’s anaesthesia versus topical anaesthesia for cataract surgery. Cochrane Database Syst Rev. 2007; 18:CD006291. https://doi.org/10.1002/14651858.CD006291.pub2 PMID: 17636839

41. Kwok AK, Van Newkirk MR, Lam DS, Fan DS. Sub-Tenon’s anaesthesia in vitreoretinal surgery: a needleless technique. Retina. 1999; 19:291–296. https://doi.org/10.1097/00006692-199907000-00004 PMID: 10458293

42. Frieman BJ, Friedberg MA. Globe perforation associated with subtenon’s anesthesia. Am J Ophthalmol. 2001; 131:520–521. https://doi.org/10.1016/s0002-9994(00)00815-1 PMID: 11292426

43. Kumar CM, Eid H, Dodds C. Sub-Tenon’s anaesthesia: complications and their prevention. Eye (Lond). 2011; 25:694–703.

44. Sohn HJ, Moon HS, Nam DH, Paik HJ. Effect of volume used in sub-Tenon’s anaesthesia on efficacy and intraocular pressure in vitreoretinal surgery. Ophthalmologica. 2008; 222:414–421. https://doi.org/10.1159/000161556 PMID: 18849625

45. Feibel RM, Guyton DL. Transient Central Retinal Artery Occlusion after Posterior Sub-Tenon’s Anesthesia. J Cataract Refract Surg. 2003; 29:1821–1824. https://doi.org/10.1016/s0886-3350(02)01975-2 PMID: 14522307

46. Farmery AD, Sluga-D, Rahman R, Rosen P. Sub-Tenon’s block reduces both intraoperative and postoperative analgesia requirement in vitreo-retinal surgery under general anaesthesia. Eur J Anaesthesiol. 2003; 20:973–978. https://doi.org/10.1017/s0265021503001571 PMID: 14690100

47. Segal O, Segal-Trivitz Y, Nemet AY, Cohen P, Geffen N, Mimouni M. Anxiety levels and perceived pain intensity during intravitreal injections. Acta Ophthalmol. 2016; 94:203–204. https://doi.org/10.1111/aos.12802 PMID: 26215781

48. Socca SD, Abuhalas H, Magen O, Zayit-Soudry S, Blumenthal EZ, Duvedev N, et al. Preoperative Anxiety Levels and Pain during Cataract Surgery. Curr Eye Res. 2019 Sep 18:1–6. https://doi.org/10.1080/02713683.2019.1666996 [Epub ahead of print] PMID: 31509020

49. Baus YM, Trope GE. Prospective study of sub-Tenon’s versus retrobulbar anaesthesia for inpatient and day-surgery trabeculectomy. Ophthalmology. 1993; 100:1585–1589. https://doi.org/10.1016/s0161-6420(93)31440-5 PMID: 8414420

50. Kumar CM, Dodds C. Sub-Tenon’s Anaesthesia. Ophthalmol Clin North Am. 2006; 19:209–219. https://doi.org/10.1016/j.ohc.2006.02.008 PMID: 16701158

51. Steele MA, Lavrich JB, Nelson LB, Kolier HP. Sub-Tenon’s infusion of local anesthetic for strabismus surgery. Ophthalmic Surg. 1992; 23:40–43. PMID: 1574266

52. Sharma T, Gopal L, Parikh S, Shanmugam MP, Badrinath SS, Mukesh BN. Parabulbar anesthesia for primary vitreoretinal surgery. Ophthalmology. 1997; 104:425–428. https://doi.org/10.1016/s0161-6420(97)30297-8 PMID: 9082267

53. El Matri L, Limaer M, Mghaieth F, Bukta M, El Asmi W. [Subtenon anesthesia by single injection at the inner canthus for surgery of the posterior segment]. Bull Soc Belge Ophtalmol. 2005;(296) :27–35. PMID: 16050417

54. Theocharis IP, Alexandridou A, Tomic Z. A two-year prospective study comparing lidocaine 2% jelly versus peribulbar anaesthesia for 25G and 23G sutureless vitrectomy. Graefes Arch Clin Exp Ophthalmol. 2007; 245:1253–1258. https://doi.org/10.1007/s00417-007-0556-y PMID: 17342504